Citeline expands partnership with Recursion for clinical trials

NEW YORK and SALT LAKE CITY - Citeline announced an expanded partnership with Recursion (NASDAQ:RXRX) on Tuesday to integrate real-world data capabilities into the biotech company’s drug development platform.

The collaboration adds Citeline’s real-world data and evidence capabilities to Recursion’s existing platform, which combines multimodal datasets, AI models, and experimental biology. The integration aims to support trial design, site selection, and development decisions, according to a press release statement.

Recursion CEO Najat Khan said the addition of Citeline’s data capabilities has supported the company’s pipeline, including contextualization of single-arm data from its REC-4881 Phase I/II study. Khan stated that investment in Recursion’s ClinTech platform has yielded 30-60% improvements in enrollment.The partnership announcement comes as Recursion’s stock trades near its 52-week low of $2.80, down 46% over the past year. Despite the stock’s recent struggles, InvestingPro data shows 5 analysts have revised their earnings upwards for the upcoming period, suggesting growing confidence in the company’s direction. The company maintains a market capitalization of $1.51 billion.

"Recursion has been an exceptional partner to Norstella and Citeline, consistently pushing the boundaries of what’s possible at the intersection of biology, technology, and data," said Fred Hassan, Executive Chair of Norstella, Citeline’s parent company.

Citeline provides business intelligence solutions for the life sciences industry, offering data analysis tools for clinical, commercial, and regulatory decisions. The company’s services include coverage of clinical trials, drug research and development, and market forecasts.

Recursion operates as a clinical-stage technology-biology company with a portfolio of investigational medicines in oncology, rare disease, neuroscience, and immunology. The company’s platform, Recursion OS, integrates biology, chemistry, and clinical development using proprietary data and AI models.While the company reported 27% revenue growth in the last twelve months, it remains unprofitable with a strong current ratio of 5.5, indicating solid liquidity. According to InvestingPro analysis, the stock appears undervalued at current levels. For deeper insights, investors can access Recursion’s comprehensive Pro Research Report, one of 1,400+ available reports that transform complex data into actionable intelligence.

The partnership represents an expansion of an existing relationship between the two companies, with Citeline’s SmartSolutions being integrated into Recursion’s platform to provide data access during early development stages.

In other recent news, Recursion Pharmaceuticals reported a significant beat on its fourth-quarter 2025 earnings and revenue forecasts. The company announced an earnings per share (EPS) of -$0.21, outperforming the forecasted -$0.30. Additionally, Recursion’s revenue reached $35.54 million, surpassing expectations by 45%. These results indicate strong performance and have contributed to investor confidence.

Furthermore, Recursion has appointed Vicki Goodman, M.D., as Chief Medical Officer, effective April 2026. Goodman brings extensive experience in oncology drug development and medical leadership. Meanwhile, BofA Securities has lowered its price target for Recursion Pharmaceuticals from $7.00 to $6.00, maintaining a Neutral rating. The firm emphasized the need for repeatable clinical successes to demonstrate the company’s ability to translate AI-derived biology into meaningful outcomes.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.